- Home
- NXGL vs TCRT Comparison
NXGL vs TCRT Comparison
Compare NXGL & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | TCRT |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.4M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NXGL | TCRT |
|---|---|---|
| Price | $0.17 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 281.0K | ★ 410.5K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.00 | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | $11,421,000.00 | ★ $15,900,000.00 |
| Revenue This Year | $38.23 | N/A |
| Revenue Next Year | $53.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.46 | N/A |
| 52 Week Low | $0.16 | $0.78 |
| 52 Week High | $2.89 | $4.57 |
Technical Indicators
Market Signals| Indicator | NXGL | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 27.36 | 26.08 |
| Support Level | $0.16 | N/A |
| Resistance Level | $0.59 | $2.09 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 13.77 | 1.74 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.